Skip to main
PODD
PODD logo

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Insulet is well-positioned in the insulin pump market, particularly due to its differentiated product design and first-mover advantage in the Type 2 Diabetes (T2D) segment, which enhances its competitive edge. The company is demonstrating a commitment to improving gross margins, coupled with expectations of operating margin expansion of 100 basis points in both 2025 and 2026, indicating a focus on financial efficiency. Additionally, the operational adjustments in net interest expense further reflect Insulet's proactive approach to strengthening its overall financial performance.

Bears say

Insulet's 2026 operating income estimate has been revised downward to $549.3 million from $561.0 million, alongside a decrease in its EPS estimate from $6.09 to $5.74, indicating a weakening financial outlook. The anticipated introduction of competitive products poses a risk to Insulet's market position, as the company may struggle to establish itself effectively within the community before facing these headwinds. Additionally, the necessity for ongoing reductions in cost of goods sold (COGS) highlights concerns about the sustainability of Insulet's business model in the face of rising competition and potentially declining profitability.

Insulet (PODD) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 17 analysts, Insulet (PODD) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $342.35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $342.35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.